Norgine - Salamanca Free Press

Press Releases

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

Norgine

April 18, 2025

UXBRIDGE, England , April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has appro...

Press Releases

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

Norgine

April 17, 2025

UXBRIDGE, England , April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has appro...

Press Releases

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

Norgine

January 24, 2025

LONDON , Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 t...

Press Releases

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Norgine

January 7, 2025

Back to media releases Next media release LONDON , Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation ...

Salamanca Press

Get in touch with The Salamanca Press

Submit Content

Advertise

Subscribe